Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Vegetable Compound Found to Protect Against Radiation

By BiotechDaily International staff writers
Posted on 28 Oct 2013
Print article
Researchers have reported that a compound found in cruciferous vegetable such as cauliflower, cabbage, and broccoli shields rats and mice from lethal doses of radiation.

Their study, published October 15, 2013, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) suggests the compound, already demonstrated to be safe for humans, may protect healthy tissues during radiotherapy for cancer treatment and prevent or lessen sickness caused by radiation exposure.

The compound, known as DIM (3,3'-diindolylmethane), previously has been found to have cancer preventive properties. “DIM has been studied as a cancer prevention agent for years, but this is the first indication that DIM can also act as a radiation protector,” stated the study’s corresponding author, Eliot Rosen, MD, PhD, of Georgetown University Lombardi Comprehensive Cancer Center (Washington DC, USA).

The scientists irradiated rats in the study with lethal doses of gamma ray radiation. The animals were then treated with a daily injection of DIM for two weeks, starting 10 minutes after the radiation exposure. The result was amazing, according to Dr. Rosen, a professor of oncology, biochemistry, cell and molecular biology, and radiation medicine. “All of the untreated rats died, but well over half of the DIM-treated animals remained alive 30 days after the radiation exposure.”

Dr. Rosen added that DIM also provided protection whether the first injection was administered 24 hours before or up to 24 hours after radiation exposure. “We also showed that DIM protects the survival of lethally irradiated mice,” Dr. Rosen said. Furthermore, irradiated mice treated with DIM had less reduction in red blood cells, white blood cells and platelets—side effects often seen in patients undergoing radiation treatment for cancer.

Dr. Rosen noted that this study revealed two potential uses of the compound. “DIM could protect normal tissues in patients receiving radiation therapy for cancer, but could also protect individuals from the lethal consequences of a nuclear disaster.”

Rosen and study coauthors Saijun Fan, PhD, and Milton Brown, MD, PhD, are co-inventors on a patent application that has been filed by Georgetown University for the use of DIM and DIM-related compounds as radioprotectors.

Related Links:
Georgetown University Lombardi Comprehensive Cancer Center



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.